



Nebraska Medicaid DUR Board Meeting
Tuesday May 12th, 2026
In Person
Public Meeting 6:30pm
Best Western Plus Lincoln Inn & Suites
2201 Wildcat Circle Lincoln, Nebraska 68521

DRAFT pending approval at the next meeting

DUR Board Members in attendance: Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P., Jaci Timmons, M.D.

Nebraska MLTC employees in attendance: Lee Stutzman, R.P., Pharmacy Director, Leah Spencer, RN, Program Specialist, Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Michael Labadie, R.P., Molina Healthcare; Megan Petersen, R.P., United HealthCare; Shaleigh Hammons, Account Executive, Prime Therapeutics, Sandy Pranger, R.P., Sr. Director Clinical Account Services, Prime Therapeutics, Nikia Bennette-Carter, R.P., Prime Therapeutics, Renesha Yarbrough, Prime Therapeutics

Public Attendees in attendance: Kurt Hendrickson, AbbVie; Jeff Houston, AbbVie; Craig Fjeldheim, Abbvie; Jeff Martin, BioCryst; Jessi Bennett, BioCryst; Jon Freeland, Novo Nordisk

I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30 PM. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the open meetings act was available.

II. Declaration of any Conflict of Interest or changes

No changes in conflict of interest were declared.

III. Agenda approval

The agenda for the meeting was approved as follows: Broucek-yes, Moore-yes, Timmons-yes, Titchener-yes

IV. Review and Approval of Minutes from previous Board meeting January 13th 2026

The meeting minutes were approved as follows: Broucek-yes, Moore-yes, Timmons-yes, Titchener-yes.

V. Update on Recommendations from Previous Meeting

No new updates were given.

VI. Retrospective DUR

Old Business

Spencer Moore reviewed the Buprenorphine Clinical Guidance Document. No changes to the document were proposed.

New Business

Spencer Moore presented data on stroke prevention in atrial fibrillation, and the benefits of switching from warfarin to direct oral anticoagulants (DOACs). The board reviewed the data which identified some patients may be eligible to switch from warfarin to a DOAC. The board proposed that the State collaborate with the MCOs to determine if the patients identified are eligible for conversion. A motion to collaborate with the MCOs was made by Titchener and voted on as follows: Broucek-yes, Moore-yes, Timmons-yes, Titchener-yes

VII. Prospective DUR

Old Business

Fee-For-Service PA annual review

Dianne Garside presented the Hepatitis C Prior Authorization form revisions. An AbbVie representative provided public comment. A motion to approve the document as presented was made by Titchener and approved as follows: Broucek-yes, Moore-yes, Timmons-yes, Titchener-yes

Dianne Garside presented the Hereditary Angioedema Prior Authorization form revisions. A representative from BioCryst provided public comment. A typo was identified and a motion to approve the document with corrections was made by Timmons and approved as follows: Broucek-yes, Moore-yes, Timmons-yes, Titchener-yes

New Business

None.

VIII. Special Requests from the Department

None.

IX. Future Meeting Dates

August 18th 2026, October 27th 2026, and January 12th 2027

X. Concerns and Comments from the DUR Board

Charles Moore raised questions about NADAC surveys and pricing.

XI. Concerns and Comments from the DUR Director

Lee Stutzman notes that former Nebraska DHHS Chief of Staff Carisa Schweitzer-Masek has taken a role with the federal government and is no longer with the State. Stutzman stated he has taken on more responsibility as a result of this departure, but will remain as DUR Director.

XII. Concerns and Comments from the State DHHS Representatives

None.

XIII. Concerns and Comments from the MCO Representatives

None.

XIV. Concerns and Comments from the Public Attendees

None.

XV. Adjournment

Motion to adjourn the meeting was approved at 7:11pm. No objections were made from the Board.

DRAFT